Page contentsPage contents Key facts Decision Key facts Active substance vidofludimus calcium Therapeutic area Nervous system disorders Decision number EMA/PE/0000227151 PIP number EMA/PE/0000227151 Pharmaceutical form(s) Tablet Condition(s) / indication(s) Treatment of multiple sclerosis Route(s) of administration Oral use Contact for public enquiries Immunic AG Tel. +49 89 2080 477 00 E-mail: info@imux.com Decision type W: decision granting a waiver in all age groups for all conditions or indications Decision date 14/04/2025 Compliance check done No Decision EMA/PE/0000227151: EMA decision of 14 April 2025 on the granting of a product specific waiver for vidofludimus calciumAdopted Reference Number: EMADOC-1700519818-2035630 English (EN) (190.07 KB - PDF)First published: 01/07/2026 View Share this page